APP and Cognitive impairment: In our study, we would investigate the drug loading capacity, drug release kinetics, blood compatibility, cell viability, and cellular uptake of PLGA-PEG-B6/Cur in vitro and administrated it into APP/PS1 transgenic mice to evaluate its effect on cognitive impairment, Aβ, and tau pathologies by conducting Morris water maze, Bielschowsky silver staining, immunostaining, and western blotting.